Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds

Journal of Virology

Volumn 84, Issue 15, 2010, Pages 7558-7568

  Yoshimura, Kazuhisa ^a   Harada, Shigeyoshi ^a   Shibata, Junji ^a   Hatada, Makiko ^a   Yamada, Yuko ^b   Ochiai, Chihiro ^b   Tamamura, Hirokazu ^b   Matsushita, Shuzo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CD4 ANTIGEN; ENVELOPE PROTEIN; GLYCOPROTEIN GP 120; MONOCLONAL ANTIBODY; N (4 CHLOROPHENYL) N' (2,2,6,6 TETRAMETHYLPIPERIDIN 4 YL)OXALAMIDE; PIPERIDINE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; YYA 004;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL SURFACE; CHEMICAL STRUCTURE; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; VIRUS ISOLATION; VIRUS STRAIN;

ANTIBODIES, NEUTRALIZING; ANTIVIRAL AGENTS; EPITOPES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; OXALATES; PIPERIDINES; PROTEIN BINDING; VIRUS ATTACHMENT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77954525340     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00227-10     Document Type: Article

References (35)

1. Blish, C. A., R. Nedellec, K. Mandaliya, D. E. Mosier, and J. Overbaugh. 2007. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS 21:693-702.
2. Bunnik, E. M., L. Pisas, A. C. van Nuenen, and H. Schuitemaker. 2008. Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J. Virol. 82:7932-7941.
3. Burton, D. R. 2002. Antibodies, viruses, and vaccines. Nat. Rev. Immunol. 2:706-713.
4. Burton, D. R., R. C. Desrosiers, R. W. Doms, W. C. Koff, P. D. Kwong, J. P. Moore, G. J. Nabel, J. Sodroski, I. A. Wilson, and R. T. Wyatt. 2004. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5:233-236.
5. Burton, D. R., R. L. Stanfield, and I. A. Wilson. 2005. Antibody versus HIV in a clash of evolutionary titans. Proc. Natl. Acad. Sci. U. S. A. 102:14943-14948.
6. Chou, T. C., and P. Talaly. 1977. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J. Biol. Chem. 252:6438-6442.
7. Davis, K. L., F. Bibollet-Ruche, H. Li, J. M. Decker, O. Kutsch, L. Morris, A. Salomon, A. Pinter, J. A. Hoxie, B. H. Hahn, P. D. Kwong, and G. M. Shaw. 2009. Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. J. Virol. 83:1240-1259.
8. Davis, K. L., E. S. Gray, P. L. Moore, J. M. Decker, A. Salomon, D. C. Montefiori, B. S. Graham, M. C. Keefer, A. Pinter, L. Morris, B. H. Hahn, and G. M. Shaw. 2009. High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Virology 387:414-426.
9. Decker, J. M., F. Bibollet-Ruche, X. Wei, S. Wang, D. N. Levy, W. Wang, E. Delaporte, M. Peeters, C. A. Derdeyn, S. Allen, E. Hunter, M. S. Saag, J. A. Hoxie, B. H. Hahn, P. D. Kwong, J. E. Robinson, and G. M. Shaw. 2005. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J. Exp. Med. 201:1407-1419.
10. Derdeyn, C. A., J. M. Decker, F. Bibollet-Ruche, J. L. Mokili, M. Muldoon, S. A. Denham, M. L. Heil, F. Kasolo, R. Musonda, B. H. Hahn, G. M. Shaw, B. T. Korber, S. Allen, and E. Hunter. 2004. Envelope-constrained neutralization- sensitive HIV-1 after heterosexual transmission. Science 303:2019-2022. (Pubitemid 38393277)
11. Eda, Y., T. Murakami, Y. Ami, T. Nakasone, M. Takizawa, K. Someya, M. Kaizu, Y. Izumi, N. Yoshino, S. Matsushita, H. Higuchi, H. Matsui, K. Shinohara, H. Takeuchi, Y. Koyanagi, N. Yamamoto, and M. Honda. 2006. Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection. J. Virol. 80:5563-5570.
12. Eda, Y., M. Takizawa, T. Murakami, H. Maeda, K. Kimachi, H. Yonemura, S. Koyanagi, K. Shiosaki, H. Higuchi, K. Makizumi, T. Nakashima, K. Osatomi, S. Tokiyoshi, S. Matsushita, N. Yamamoto, and M. Honda. 2006. Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif. J. Virol. 80:5552-5562.
13. Guex, N., A. Diemand, and M. C. Peitsch. 1999. Protein modeling for all. Trends Biochem. Sci. 24:364-367.
14. Haim, H., Z. Si, N. Madani, L. Wang, J. R. Courter, A. Princiotto, A. Kassa, M. DeGrace, K. McGee-Estrada, M. Mefford, D. Gabuzda, A. B. Smith III, and J. Sodroski. 2009. Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS Pathog. 5:e1000360.
15. Halgren, T. A. 1996. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J. Comput. Chem. 17:490-519.
16. Hatada, M., K. Yoshimura, S. Harada, J. Shibata, and S. Matsushita. 2010. HIV-1 evasion of a neutralizing anti-V3 antibody involves acquisition of a potential glycosylation site in V2. J. Gen. Virol. 91:1335-1345.
17. Hope, T. J., X. J. Huang, D. McDonald, and T. G. Parslow. 1990. Steroidreceptor fusion of the human immunodeficiency virus type 1 Rev transactivator: mapping cryptic functions of the arginine-rich motif. Proc. Natl. Acad. Sci. U. S. A. 87:7787-7791.
18. Johnson, W. E., and R. C. Desrosiers. 2002. Viral persistence: HIV's strategies of immune system evasion. Annu. Rev. Med. 53:499-518.
19. Kimura, T., K. Yoshimura, K. Nishihara, Y. Maeda, S. Matsumi, A. Koito, and S. Matsushita. 2002. Reconstitution of spontaneous neutralizing antibody response against autologous human immunodeficiency virus during highly active antiretroviral therapy. J. Infect. Dis. 185:53-60.
20. Kwong, P. D., R. Wyatt, J. Robinson, R. W. Sweet, J. Sodroski, and W. A. Hendrickson. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659.
21. Lu, M., S. C. Blacklow, and P. S. Kim. 1995. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 2:1075-1082.
22. Lusso, P., P. L. Earl, F. Sironi, F. Santoro, C. Ripamonti, G. Scarlatti, R. Longhi, E. A. Berger, and S. E. Burastero. 2005. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains. J. Virol. 79:6957-6968.
23. Madani, N., A. Schon, A. M. Princiotto, J. M. Lalonde, J. R. Courter, T. Soeta, D. Ng, L. Wang, E. T. Brower, S. H. Xiang, Y. D. Kwon, C. C. Huang, R. Wyatt, P. D. Kwong, E. Freire, A. B. Smith III, and J. Sodroski. 2008. Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure 16:1689-1701.
24. Maeda, Y., K. Yusa, and S. Harada. 2008. Altered sensitivity of an R5X4 HIV-1 strain 89.6 to coreceptor inhibitors by a single amino acid substitution in the V3 region of gp120. Antivir. Res. 77:128-135.
25. Schön, A., N. Madani, J. C. Klein, A. Hubicki, D. Ng, X. Yang, A. B. Smith III, J. Sodroski, and E. Freire. 2006. Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. Biochemistry 45:10973-10980.
26. Shibata, J., K. Yoshimura, A. Honda, A. Koito, T. Murakami, and S. Matsushita. 2007. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate. J. Virol. 81:3757-3768.
27. Thali, M., J. P. Moore, C. Furman, M. Charles, D. D. Ho, J. Robinson, and J. Sodroski. 1993. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 67:3978-3988. (Pubitemid 23180722)
28. Wang, F. X., T. Kimura, K. Nishihara, K. Yoshimura, A. Koito, and S. Matsushita. 2002. Emergence of autologous neutralization-resistant variants from preexisting human immunodeficiency virus (HIV) quasispecies during virus rebound in HIV type 1-infected patients undergoing highly active antiretroviral therapy. J. Infect. Dis. 185:608-617.
29. Wyatt, R., P. D. Kwong, E. Desjardins, R. W. Sweet, J. Robinson, W. A. Hendrickson, and J. G. Sodroski. 1998. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705-711.
30. Yamada, Y., C. Ochiai, K. Yoshimura, T. Tanaka, N. Ohashi, T. Narumi, W. Nomura, S. Harada, S. Matsushita, and H. Tamamura. 2010. CD4 mimics targeting the mechanism of HIV entry. Bioorg. Med. Chem. Lett. 20:354-358.
31. Yoshimura, K., R. Kato, M. F. Kavlick, A. Nguyen, V. Maroun, K. Maeda, K. A. Hussain, A. K. Ghosh, S. V. Gulnik, J. W. Erickson, and H. Mitsuya. 2002. A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site. J. Virol. 76:1349-1358.
32. Yoshimura, K., R. Kato, K. Yusa, M. F. Kavlick, V. Maroun, A. Nguyen, T. Mimoto, T. Ueno, M. Shintani, J. Falloon, H. Masur, H. Hayashi, J. Erickson, and H. Mitsuya. 1999. JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. Proc. Natl. Acad. Sci. U. S. A. 96:8675-8680.
33. Yoshimura, K., J. Shibata, T. Kimura, A. Honda, Y. Maeda, A. Koito, T. Murakami, H. Mitsuya, and S. Matsushita. 2006. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors. AIDS 20:2065-2073.
34. Yusa, K., Y. Maeda, A. Fujioka, K. Monde, and S. Harada. 2005. Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 loop library. J. Biol. Chem. 280:30083-30090.
35. Zhao, Q., L. Ma, S. Jiang, H. Lu, S. Liu, Y. He, N. Strick, N. Neamati, and A. K. Debnath. 2005. Identification of N-phenyl-N′-(2,2,6,6- tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology 339:213-225.